Published in Cancer Biol Ther on August 13, 2008
Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell (2010) 2.20
Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proc Natl Acad Sci U S A (2010) 2.07
miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J (2011) 1.98
Role of miR-34c microRNA in the late steps of spermatogenesis. RNA (2010) 1.60
Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J (2011) 1.42
Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med (2011) 1.38
Helicobacter pylori induces miR-155 in T cells in a cAMP-Foxp3-dependent manner. PLoS One (2010) 1.35
Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One (2012) 1.30
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol (2010) 1.28
MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J Biol Chem (2011) 1.23
MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas. J Oral Maxillofac Res (2013) 1.22
Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer (2011) 1.20
Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport. Physiol Rev (2012) 1.18
Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med (2010) 1.10
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene (2012) 1.08
Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer. PLoS One (2013) 1.06
Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells. Radiat Res (2012) 1.06
MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) (2013) 1.04
MicroRNA-34c enhances murine male germ cell apoptosis through targeting ATF1. PLoS One (2012) 1.03
miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. Breast Cancer Res (2011) 1.03
MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One (2013) 1.03
Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol (2013) 0.95
MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget (2015) 0.90
CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis. Adv Hematol (2009) 0.88
The Potential of MicroRNAs as Prostate Cancer Biomarkers. Eur Urol (2016) 0.88
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer (2011) 0.86
MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol (2012) 0.86
Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer (2012) 0.84
Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev (2012) 0.84
MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples. Biomed Res Int (2014) 0.83
Cellular Response to Ionizing Radiation: A MicroRNA Story. Int J Mol Cell Med (2012) 0.82
USP2a alters chemotherapeutic response by modulating redox. Cell Death Dis (2013) 0.82
Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype. BMC Dev Biol (2010) 0.82
LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a. Mol Cancer Res (2015) 0.82
Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer. IUBMB Life (2014) 0.79
The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.78
MicroRNAs in inner ear biology and pathogenesis. Hear Res (2012) 0.78
MicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer. Front Genet (2011) 0.77
The role of microRNAs in prostate cancer progression. Transl Androl Urol (2013) 0.77
Mir-34a mimics are potential therapeutic agents for p53-mutated and chemo-resistant brain tumour cells. PLoS One (2014) 0.77
Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis. Clin Exp Gastroenterol (2011) 0.77
Prospects of miRNA-based therapy for pancreatic cancer. Curr Drug Targets (2013) 0.76
Human serum miR-34a as an indicator of exposure to ionizing radiation. Radiat Environ Biophys (2016) 0.76
The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia (2016) 0.75
Prognostic Significance of MiR-34a Expression in Patients with Gastric Cancer after Radical Gastrectomy. Chin Med J (Engl) (2015) 0.75
Utilizing yeast chemogenomic profiles for the prediction of pharmacogenomic associations in humans. Sci Rep (2016) 0.75
Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer. Oncol Lett (2015) 0.75
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J Biol (2002) 3.85
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Implementation of virtual microscope slides in the annual pathobiology of cancer workshop laboratory. Hum Pathol (2003) 2.01
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Blood (2012) 1.94
Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply. Arch Pathol Lab Med (2013) 1.78
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate (2011) 1.68
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther (2003) 1.58
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res (2010) 1.57
Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther (2005) 1.54
TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther (2003) 1.47
Coauthorship in pathology, a comparison with physics and a survery-generated and member-preferred authorship guideline. MedGenMed (2004) 1.45
Bisindolylmaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell Death. Cancer Biol Ther (2003) 1.40
Commentary: Mentoring the mentor: executive coaching for clinical departmental executive officers. Acad Med (2010) 1.38
Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate (2002) 1.32
In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener (2008) 1.18
Mandatory second opinion in surgical pathology referral material: clinical consequences of major disagreements. Am J Surg Pathol (2008) 1.14
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene (2005) 1.12
Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res (2003) 1.10
Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res (2006) 1.09
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Achieving successful deployment of Bt rice. Trends Plant Sci (2004) 1.06
Letters to the editor. Endocr Pract (2015) 1.06
Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient. Am J Rhinol (2008) 1.06
Death receptor-induced cell death in prostate cancer. J Cell Biochem (2004) 1.05
Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res (2007) 1.05
Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther (2007) 1.04
Runx2 regulates survivin expression in prostate cancer cells. Lab Invest (2009) 1.03
Impact of small fitness costs on pest adaptation to crop varieties with multiple toxins: a heuristic model. J Econ Entomol (2006) 1.02
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res (2006) 1.02
Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res (2002) 1.02
Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. Horm Cancer (2010) 1.01
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
Effects of Bacillus thuringiensis on non-target herbivore and natural enemy assemblages in tropical irrigated rice. Environ Biosafety Res (2004) 1.00
p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology (2003) 1.00
Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate (2002) 0.94
Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res (2002) 0.93
Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Mol Ther (2008) 0.91
Bacillus thuringiensis delta-endotoxin binding to brush border membrane vesicles of rice stem borers. Arch Insect Biochem Physiol (2004) 0.91
Ddb2 is a haploinsufficient tumor suppressor and controls spontaneous germ cell apoptosis. Hum Mol Genet (2007) 0.90
Contribution of death receptor and mitochondrial pathways to Fas-mediated apoptosis in the prostatic carcinoma cell line PC3. Prostate (2002) 0.89
Pathology education: quo vadis? Hum Pathol (2008) 0.89
TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome. Cancer Biol Ther (2006) 0.88
An enhanced antigen-retrieval protocol for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues. Methods Mol Biol (2011) 0.87
Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am J Rhinol Allergy (2009) 0.86
Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer. J Biol Chem (2012) 0.86
Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. J Biol Chem (2002) 0.85
Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L). Breast Cancer Res Treat (2007) 0.85
Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor. Oncotarget (2012) 0.85
KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. Cancer Biol Ther (2010) 0.85
Overexpression of BAD potentiates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand treatment in the prostatic carcinoma cell line LNCaP. Mol Cancer Res (2003) 0.84
TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status. Cancer Biol Ther (2011) 0.83
Cytologic diagnosis of adenocarcinoma in biliary and pancreatic duct brushings. Adv Anat Pathol (2002) 0.83
Assessing implicit gender bias in Medical Student Performance Evaluations. Eval Health Prof (2010) 0.83
Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLoS One (2013) 0.82
Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines. Mol Cancer Res (2004) 0.82
Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biol Ther (2004) 0.82
Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene (2002) 0.82
Evaluating prostate cancer cell culturing methods: a comparison of cell morphologies and metabolic activity. Oncol Rep (2003) 0.81
Tissue-specific gene silencing monitored in circulating RNA. RNA (2013) 0.81
Dystroglycan is not required for maintenance of the luminal epithelial basement membrane or cell polarity in the mouse prostate. Prostate (2010) 0.80
Updated protocol for the examination of specimens from patients with carcinoma of the urinary bladder, ureter, and renal pelvis. Arch Pathol Lab Med (2003) 0.80
A preliminary diagnosis service provides prospective blinded dual-review of all general surgical pathology cases in an academic practice. Am J Surg Pathol (2005) 0.79
Contextual effect of repression of bone morphogenetic protein activity in prostate cancer. Endocr Relat Cancer (2013) 0.79
Nondestructive near-infrared spectroscopic measurement of multiple analytes in undiluted samples of serum-based cell culture media. Biotechnol Bioeng (2002) 0.79
Mandatory second opinion in cytopathology. Cancer (2009) 0.79
Long-term, tumor-free survival after radiotherapy combining hepatectomy-Whipple en bloc and orthotopic liver transplantation for early-stage hilar cholangiocarcinoma. Liver Transpl (2008) 0.79
Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts. J Cell Physiol (2014) 0.79
Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro. J Drug Target (2008) 0.78
FISHing and beyond in urinary cytology. Diagn Cytopathol (2004) 0.77
Clinical correlation between irrigation bottle contamination and clinical outcomes in post-functional endoscopic sinus surgery patients. Am J Rhinol Allergy (2009) 0.76
Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther (2006) 0.76
P53 and the proteasome regulate androgen receptor activity. Cancer Biol Ther (2012) 0.76